Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
Clinical Roundup

Cancer researchers team up against deadliest brain tumors in children

May 26, 2023
Vol.49 No.21
In Brief

Michael Taylor named director of the Pediatric Neuro-Oncology Research Program at Texas Children’s and Baylor

February 10, 2023
Vol.49 No.06
Drugs & Targets

FLAG Therapeutics’s FLAG-003 receives Rare Pediatric Disease Designation for diffuse intrinsic pontine glioma

February 03, 2023
Vol.49 No.05
Clinical Roundup

CRUK, University of Manchester, Roche trial opens for people with rare and pediatric cancers

December 09, 2022
Vol.48 No.44
In Brief

Martha Donoghue named FDA OCE associate director for pediatric oncology and rare cancers

December 02, 2022
Vol.48 No.43
In Brief

Pediatric oncologist Oksana Leontyeva killed in Russian rocket attack on Kyiv

October 21, 2022
Vol.48 No.38
Audrey Evans, trailblazing pediatric oncologist, first chief of oncology at CHOP, dies at 97
FreeObituary

Audrey Evans, trailblazing pediatric oncologist, first chief of oncology at CHOP, dies at 97

October 14, 2022
Vol.48 No.37
By John M. Maris
In Brief

Jack Martin Fund gives $3.5M to Mt. Sinai Kravis Children’s Hospital to establish child and adolescent imaging center

October 07, 2022
Vol.48 No.36
Clinical Roundup

Explanations behind possible link between increased risk of most common childhood cancer and people with obesity prior to pregnancy

September 30, 2022
Vol.48 No.35
Drugs & Targets

FDA approves Pedmark to reduce the risk of ototoxicity associated with cisplatin for localized pediatric solid tumors

September 23, 2022
Vol.48 No.34

Posts navigation

Previous1…6789Next

Trending Stories

  • Kennedy calls for a “moonshot” targeted on the role of the microbiome in cancer
  • Charles Rudin named cancer center director at MSK
  • How City of Hope is turning microbiome science into better cancer care
  • Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
  • Marcel van den Brink: Microbiome research is now in “critical phase” where evidence points to therapeutic use
  • What are you reading in 2024?

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2026 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account